These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35224552)

  • 1. FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.
    Adib E; El Zarif T; Jain RK; Skelton WP; Freeman D; Curran C; Akl E; Nassar AH; Ravi P; Mantia C; Kwiatkowski DJ; Choueiri TK; Sonpavde G
    BJUI Compass; 2022 Mar; 3(2):169-172. PubMed ID: 35224552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
    Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
    Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic alterations of
    Jindal T; Zhu X; Bose R; Kumar V; Maldonado E; Deshmukh P; Shipp C; Feng S; Johnson MS; Angelidakis A; Kwon D; Borno HT; de Kouchkovsky I; Desai A; Aggarwal R; Fong L; Small EJ; Wong A; Porten S; Chou J; Friedlander T; Koshkin VS
    Front Oncol; 2023; 13():1161089. PubMed ID: 37091148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma.
    Van Sanden S; Youssef A; Baculea S; Stubbs K; Triantos S; Yuan Z; Daly C
    J Health Econ Outcomes Res; 2024; 11(2):49-57. PubMed ID: 39267886
    [No Abstract]   [Full Text] [Related]  

  • 6. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2
    Fiala O; Massari F; Basso U; Giannatempo P; Grande E; Buti S; Myint ZW; De Giorgi U; Pichler R; Grillone F; Ürün Y; Calabrò F; Bourlon MT; Galli L; Kanesvaran R; Roviello G; Kucharz J; Rizzo M; Park SH; Cerbone L; Seront E; Messina C; Molina-Cerrillo J; Santini D; Yano A; Incorvaia L; Catalano M; Pinto A; Formisano L; Soares A; Facchini G; Fornarini G; Poprach A; Rebuzzi SE; Nasso C; Spinelli GP; Angel M; Stellato M; Tural D; Aurilio G; Epstein I; Carrozza F; Monteiro FSM; Benedetti G; Büchler T; Ortega C; Zakopoulou R; Battelli N; Porta C; Bellmunt J; Gupta S; Santoni M
    Target Oncol; 2024 Nov; 19(6):905-915. PubMed ID: 39354179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study.
    Hayakawa N; Kikuchi E; Kaneko G; Yamashita R; Ikarashi D; Endo Y; Usui K; Obara W; Oyama M; Kondo Y
    Jpn J Clin Oncol; 2024 Nov; 54(11):1194-1200. PubMed ID: 38943559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
    Zschäbitz S; Biernath N; Hilser T; Höllein A; Zengerling F; Cascucelli J; Paffenholz P; Seidl D; Lutz C; Schlack K; Kingreen D; Klümper N; Ivanyi P; von Amsberg G; Heers H; Roghmann F; Tauber RL; Cathomas R; Hofer L; Niegisch G; Klee M; Ehrenberg R; Hassler A; Hadaschik BA; Grünwald V; Darr C
    Eur Urol Open Sci; 2023 Jul; 53():31-37. PubMed ID: 37441344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience.
    Vlachou E; Johnson BA; McConkey D; Jing Y; Matoso A; Hahn NM; Hoffman-Censits J
    Front Oncol; 2024; 14():1377842. PubMed ID: 38933451
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Klümper N; Tran NK; Zschäbitz S; Hahn O; Büttner T; Roghmann F; Bolenz C; Zengerling F; Schwab C; Nagy D; Toma M; Kristiansen G; Heers H; Ivanyi P; Niegisch G; Grunewald CM; Darr C; Farid A; Schlack K; Abbas M; Aydogdu C; Casuscelli J; Mokry T; Mayr M; Niedersüß-Beke D; Rausch S; Dietrich D; Saal J; Ellinger J; Ritter M; Alajati A; Kuppe C; Meeks J; Vera Badillo FE; Nakauma-González JA; Boormans J; Junker K; Hartmann A; Grünwald V; Hölzel M; Eckstein M
    J Clin Oncol; 2024 Jul; 42(20):2446-2455. PubMed ID: 38657187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
    Matsubara N; Yonese J; Kojima T; Azuma H; Matsumoto H; Powles T; Rosenberg JE; Petrylak DP; Matsangou M; Wu C; Campbell M; Yamashiro M
    Cancer Med; 2023 Feb; 12(3):2761-2771. PubMed ID: 36052536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
    Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program.
    Monteiro FSM; Silva AGE; Gomes AJPS; Dutra C; Ferreira NO; Mariano RC; Schutz FA
    Ther Adv Med Oncol; 2021; 13():17588359211015499. PubMed ID: 34046088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfortumab vedotin - next game-changer in urothelial cancer.
    Maas M; Stühler V; Walz S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
    [No Abstract]   [Full Text] [Related]  

  • 17. Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan.
    Nakane K; Taniguchi K; Nezasa M; Enomoto T; Yamada T; Tomioka-Inagawa R; Niwa K; Tomioka M; Ishida T; Nagai S; Yokoi S; Taniguchi T; Kawase M; Kawase K; Iinuma K; Tobisawa Y; Koie T
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
    Maiorano BA; Catalano M; Maiello E; Roviello G
    Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Minato A; Kimuro R; Ohno D; Tanigawa K; Kuretake K; Matsukawa T; Takaba T; Jojima K; Harada M; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N; Miyamoto H
    Anticancer Res; 2023 Sep; 43(9):4055-4060. PubMed ID: 37648337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Taguchi S; Kawai T; Ambe Y; Kishitani K; Sugimoto K; Miyakawa J; Nakamura Y; Noda M; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Furuya Y; Sato Y; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
    Int J Urol; 2023 Dec; 30(12):1180-1186. PubMed ID: 37740409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.